Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype.
Vedolizumab, a gut-homing α4β7 integrin antagonist, has demonstrated efficacy in ulcerative colitis and Crohn's disease. Development of progressive multifocal leukoencephalopathy, a serious brain infection associated with natalizumab (an α4β7 and α4β1 integrin antagonist), has raised concern that vedolizumab may convey a similar risk. Natalizumab is believed to impair central nervous system immune surveillance by affecting cerebrospinal fluid (CSF) lymphocyte counts and the CD4:CD8 ratio. To determine if vedolizumab elicits similar effects, we examined CSF of healthy volunteers by flow cytometry for T-lymphocyte surface markers 5 weeks after administration of intravenous vedolizumab 450 mg. No significant changes were observed in CSF T-lymphocyte populations.
Millennium Pharmaceuticals, Inc., a Takeda Company, 35 Landsdowne St., Cambridge, MA 02139, USA.
Catherine
C
Milch
Tim
T
Wyant
Jing
J
Xu
Asit
A
Parikh
Whitney
W
Kent
Irving
I
Fox
Joseph
J
Berger
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood / Q000494:pharmacology*; D015703:Antigens, CD / Q000378:metabolism; D002555:Cerebrospinal Fluid / Q000166:cytology*; D005260:Female; D006801:Humans; D016023:Integrins / Q000276:immunology*; D008297:Male; D013601:T-Lymphocytes / Q000187:drug effects*; D055815:Young Adult
D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D016023:Integrins; C071777:integrin alpha4beta7; C543529:vedolizumab
Cerebrospinal fluid; Immune surveillance; Inflammatory bowel disease; Vedolizumab